{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149"}]}],"title":"Number of TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"73"}]}],"title":"Number of treatment related TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"}]}],"title":"Number of NPI-0052 related TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"}]}],"title":"Number of grade ≥3 TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Number of treatment related grade ≥3 TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Number of NPI-0052 realted grade ≥3 TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"Number of serious TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Number of treatment related serious TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Number of NPI-0052 related serious TEAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Adverse events were graded using NCI-CTCAE (version 4.3). TEAEs are defined as any adverse event with an onset date between the date of first dose and 30 days after the date of last dose of any study drug.\n\nTreatment-related adverse events are adverse events considered related to at least one study drug by the investigator (NPI-002, dexamethasone), including those with unknown relationship.","groups":[{"description":"Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles","id":"OG000","title":"MRZ 0.5 mg/m^2"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Through study completion, an average of 6.09 weeks.","title":"Number of Treatment Emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"TEAEs"}